Summit (oxford) Limited

Peter Timmins

Jean-Francois Carniaux

Laura Trespidi

Francis X Wilson

The present invention relates to solid tablet oral dosage forms of 2,2'-di(pyridin-4-yl)-1H,1′H-5,5′-bibenzo[d]imidazole (which may also be known as 2,2′-di-4-pyridinyl-6,6′-bi-1H-benzimidazole; 5,5′-bis[2-(4-pyridinyl)-1H-benzimidazole]; 2,2′-bis(4-pyridyl)-3H,3′H-5,5′-bibenzimidazole; or 2-pyridin-4-yl-6-(2-pyridin-4-yl-3H-benzimidazol-5-yl)-1H-benzimidazole), referenced herein by the INN name ridinilazole, and pharmaceutically acceptable derivatives, salts, hydrates, solvates, complexes, bioisosteres, metabolites or prodrugs thereof.

Growing community of inventors

Ellesmere Port, United Kingdom

Peter Timmins